Medications categorized as Janus kinase (JAK) inhibitors—widely prescribed to manage chronic inflammatory conditions—have been identified by researchers at the Norwegian University of Science and Technology (NTNU) as potentially increasing the susceptibility of patients to viral infections. While these drugs are essential for treating autoimmune disorders like rheumatoid arthritis and psoriasis, the new study, published in the journal NAR Molecular Medicine, suggests that their mechanism of action inadvertently suppresses the body’s primary antiviral defense systems.
The research indicates that by inhibiting the signaling pathways necessary for an immune response, these drugs may inadvertently provide a gateway for viruses such as SARS-CoV-2, influenza A, and the Rift Valley fever virus to infect cells more effectively and proliferate throughout the body.
The Mechanism of Action: How JAK Inhibitors Function
JAK inhibitors belong to a class of small-molecule drugs that block the activity of one or more of the Janus kinase enzymes (JAK1, JAK2, JAK3, and TYK2). These enzymes are intracellular signaling molecules that transmit signals from cytokine receptors on the cell surface to the nucleus, where they trigger the transcription of specific genes.
In a healthy immune system, this pathway is vital for the production of interferons—proteins released by host cells in response to the presence of pathogens. Interferons act as a "first responder" system, signaling neighboring cells to heighten their antiviral defenses. By blocking the JAK-STAT pathway, these medications effectively "turn down the volume" on the body’s inflammatory response, which is why they are so effective at treating conditions like rheumatoid arthritis, where the immune system is overactive. However, the NTNU research demonstrates that this same silencing effect prevents the cell from responding appropriately when a virus attempts to breach the cellular membrane.
Chronology of the Study and Experimental Methodology
The investigation into the trade-offs of JAK inhibitors was a multi-disciplinary effort spearheaded by Professor Denis Kainov and his team at the Department of Clinical and Molecular Medicine at NTNU. The study began with a hypothesis that the suppression of immune signaling might have downstream consequences for viral replication.
To test this, the researchers employed a robust experimental framework that moved beyond simple cell cultures. The team utilized:
- Gene expression analysis: Mapping how specific genes responsible for antiviral protection are downregulated when JAK inhibitors are introduced.
- Organoid technology: Growing miniature, three-dimensional models of human organs—including lung, eye, and brain tissues—in a laboratory setting. This provided a more accurate representation of how a human organ would react to a drug compared to flat, two-dimensional cell cultures.
- Comparative virology: Exposing both treated and untreated organoid models to various viral pathogens, including SARS-CoV-2 and influenza, to measure the rate of viral spread.
The results consistently showed that in the presence of JAK inhibitors, the antiviral gene response was significantly blunted. This lack of resistance allowed viruses to penetrate deeper into the organoid structures, establishing infections that were otherwise contained in the control groups.
Supporting Data and Clinical Context
The implications of these findings are significant, particularly given the global reliance on JAK inhibitors. Since the approval of the first JAK inhibitor, tofacitinib, by the U.S. Food and Drug Administration (FDA) in 2012, the class has expanded to include medications such as baricitinib, ruxolitinib, and upadacitinib. These drugs have revolutionized the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and myelofibrosis.
However, the medical community has long been aware of the "black box" warnings associated with these medications. Manufacturers are required to state that patients taking JAK inhibitors are at a higher risk of developing serious infections. The NTNU study provides the molecular explanation for why this clinical observation exists, specifically linking it to the suppression of the interferon-mediated antiviral defense.
According to data from the Centers for Disease Control and Prevention (CDC) and various clinical trials, patients on immunosuppressive therapy are often excluded from or monitored heavily during clinical trials for infectious diseases. The NTNU research adds a layer of precision to these warnings: it is not merely that these patients are "immunocompromised," but that their cellular "alarm system" for viruses has been effectively silenced by their daily medication.
Official Responses and Academic Perspectives
The research team, led by PhD fellow Erlend Ravlo and co-author Aleksandr Ianevski, emphasizes that their findings are not a call to abandon the use of JAK inhibitors. Instead, they represent a critical update to the pharmacological risk-benefit profile.
"JAK inhibitors are often prescribed for autoimmune diseases and inflammatory conditions such as rheumatoid arthritis," says Ravlo. "Although these medications can be highly effective at reducing inflammation, their benefits come with an important trade-off. By suppressing certain immune responses, they can also interfere with the mechanisms that normally protect the body from viral infections."
The scientific community is responding with a call for more personalized prescribing practices. While the research was conducted at NTNU, the implications resonate with international rheumatology and immunology societies. Experts suggest that clinicians should evaluate the local prevalence of viral outbreaks—such as influenza surges or COVID-19 waves—before adjusting dosages or considering temporary cessation of JAK inhibitors in high-risk patients.
Broader Impact and Implications for Future Treatment
The findings present a dual-edged sword for the medical and research communities. While the side effect is undoubtedly a risk for patients, the ability to manipulate the JAK-STAT pathway under controlled laboratory conditions offers a unique tool for researchers.
Research Applications
In a laboratory setting, researchers can use JAK inhibitors to intentionally suppress antiviral defenses in cells. This allows scientists to create "susceptible" models, which are useful for:
- Evaluating the efficacy of new antiviral drug candidates.
- Studying the basic biology of how viruses replicate in human tissue.
- Developing and testing vaccine candidates by observing how they interact with cells that have limited immune interference.
Clinical Implications
For the practicing physician, the research underscores the need for a heightened index of suspicion. If a patient on a JAK inhibitor presents with symptoms of a viral infection, the illness may progress more rapidly or reach a higher viral load than it would in a patient with an intact immune system.
Furthermore, the study suggests a potential need for "stratified prescribing." This involves screening patients for latent viral infections before starting long-term JAK inhibitor therapy and monitoring them more closely during peak viral transmission seasons.
Conclusion: Moving Toward Precision Immunotherapy
The research conducted at NTNU serves as a reminder that the human immune system is a delicate balance of competing forces. Inflammation is a necessary protective response, but when it becomes chronic, it causes tissue damage, necessitating the use of immunosuppressants. By uncovering the specific molecular interference caused by JAK inhibitors, the NTNU team has provided a roadmap for safer drug use.
As the field of medicine moves toward more personalized care, the insights from this study will likely inform new guidelines for the management of autoimmune conditions during global health crises. The goal is to maximize the therapeutic benefits of JAK inhibitors while minimizing the "hidden" vulnerability they create. As Professor Kainov and his colleagues continue their work, the focus remains on optimizing these treatments to ensure that patients can manage their chronic conditions without sacrificing their inherent capacity to fight off viral threats.
This research was made possible through the collaboration of the Department of Clinical and Molecular Medicine at NTNU, with significant funding and expertise provided by Professor Magnar Bjørås. The project also received support from the Central Norway Regional Health Authority, the South-Eastern Norway Regional Health Authority, the Research Council of Norway, and the Swedish Research Council, reflecting the international importance of understanding the interaction between inflammatory regulation and viral defense.
